Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ODM-201 plus androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer
MOH_2017-03-14_000223Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing ADT + docetaxel + ODM-201 with ADT + docetaxel + placebo (2 arms). Started Aug 2016; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2017-03-14_000223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000223.